Pretreatment Patient Characteristics
| . | Cladribine + Filgrastim (treated group) . | Cladribine Alone (historic controls) . | P Value . |
|---|---|---|---|
| No. of patients | 35 | 105 | |
| Age (yr): median (range) | 52 (34-75) | 53 (28-77) | .57 |
| Sex: males/females | 31/4 | 81/24 | .22 |
| Pretreatment duration (mo) | |||
| Median (range) | 22 (1-193) | 23 (1-192) | .59 |
| Spleen size (%): | |||
| Absent (splenectomized) | 4 (11%) | 35 (33%) | .03* |
| Nonpalpable | 13 (37%) | 16 (15%) | |
| 1-2 fingerbreadths | 5 (14%) | 11 (10%) | |
| 3-4 fingerbreadths | 9 (26%) | 24 (23%) | |
| >5 fingerbreadths | 4 (11%) | 16 (15%) | |
| Unknown | 0 | 3 (3%) | |
| Prior Treatment (%): | |||
| None | 13 (37%) | 41 (39%) | 10−4* |
| Splenectomy | 0 | 16 (15%) | |
| Interferon | 4 (11%) | 27 (26%) | |
| Splenectomy/Interferon | 0 | 19 (18%) | |
| Pentostatin/Interferon | 0 | 2 (2%) | |
| Cladribine | 12 (34%) | 0 | |
| Splenectomy/Interferon/Cladribine | 3 (9%) | 0 | |
| Interferon/Cladribine | 1 (3%) | 0 | |
| Other | 2 (6%) | 0 | |
| Peripheral blood counts | |||
| WBC (×109/L) | |||
| Median (range) | 2.3 (1.3-23.3) | 3.4 (0.6-78.8) | .13 |
| ANC (×109/L) | |||
| Median (range) | 0.9 (0.08-2.56) | 0.9 (0.07-4.32) | .75 |
| Hemoglobin (g/dL) | |||
| Median (range) | 13 (7.4-15.8) | 11.9 (5.2-16.2) | .07 |
| Platelets (×109/L) | |||
| Median (range) | 87 (34-187) | 83 (19-468) | .83 |
| Absolute hairy cell count (×106/L) | |||
| Median (range) | 83 (0-18,174) | 164 (0-60,345) | .09 |
| . | Cladribine + Filgrastim (treated group) . | Cladribine Alone (historic controls) . | P Value . |
|---|---|---|---|
| No. of patients | 35 | 105 | |
| Age (yr): median (range) | 52 (34-75) | 53 (28-77) | .57 |
| Sex: males/females | 31/4 | 81/24 | .22 |
| Pretreatment duration (mo) | |||
| Median (range) | 22 (1-193) | 23 (1-192) | .59 |
| Spleen size (%): | |||
| Absent (splenectomized) | 4 (11%) | 35 (33%) | .03* |
| Nonpalpable | 13 (37%) | 16 (15%) | |
| 1-2 fingerbreadths | 5 (14%) | 11 (10%) | |
| 3-4 fingerbreadths | 9 (26%) | 24 (23%) | |
| >5 fingerbreadths | 4 (11%) | 16 (15%) | |
| Unknown | 0 | 3 (3%) | |
| Prior Treatment (%): | |||
| None | 13 (37%) | 41 (39%) | 10−4* |
| Splenectomy | 0 | 16 (15%) | |
| Interferon | 4 (11%) | 27 (26%) | |
| Splenectomy/Interferon | 0 | 19 (18%) | |
| Pentostatin/Interferon | 0 | 2 (2%) | |
| Cladribine | 12 (34%) | 0 | |
| Splenectomy/Interferon/Cladribine | 3 (9%) | 0 | |
| Interferon/Cladribine | 1 (3%) | 0 | |
| Other | 2 (6%) | 0 | |
| Peripheral blood counts | |||
| WBC (×109/L) | |||
| Median (range) | 2.3 (1.3-23.3) | 3.4 (0.6-78.8) | .13 |
| ANC (×109/L) | |||
| Median (range) | 0.9 (0.08-2.56) | 0.9 (0.07-4.32) | .75 |
| Hemoglobin (g/dL) | |||
| Median (range) | 13 (7.4-15.8) | 11.9 (5.2-16.2) | .07 |
| Platelets (×109/L) | |||
| Median (range) | 87 (34-187) | 83 (19-468) | .83 |
| Absolute hairy cell count (×106/L) | |||
| Median (range) | 83 (0-18,174) | 164 (0-60,345) | .09 |
Nominally significant at α level .05 (P < .05).